Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab with ipilimumab for previously untreated locally advanced non-small-cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation	Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Osmertinib neoadjuvant for treating EGFR mutation positive resectable non-squamous non- small cell lung cancer	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2024	View \| Download
Patritumab deruxtecan for previously treated metastatic or locally advanced EGFR mutated non-small-cell lung cancer	Patritumab deruxtecan	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2024	View \| Download
Pegargiminase in addition to pemetrexed and cisplatin for advanced malignant pleural mesothelioma – first line	Cisplatin (Platinol) , Pegargiminase (ADI-PEG 20) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2018	View \| Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line	Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download